Compare Abeona Therapeutics Inc (ABEO) vs Petróleo Brasileiro SA (PBR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Petróleo Brasileiro SA — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Petróleo Brasileiro SA trades at $17.28 (market cap $102.10B). The key difference: Petróleo Brasileiro SA is far larger — about 273.5× Abeona Therapeutics Inc's market cap, and Petróleo Brasileiro SA pays a 10.58% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PBR | |
|---|---|---|
Market Cap | $373.32M | $102.10B |
Sector | Health | Technology |
52-Week High | $7.23 | $22.03 |
52-Week Low | $4.17 | $11.54 |
Enterprise Value | $228.22M | $164.64B |
Dividend Yield | — | 10.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PBR trades at $16.26, up 0.93% with a bearish technical outlook despite strong fundamentals. The company reported $488.72B revenue and $107.58B net income for 2025, with attractive valuation metrics including a 5.18 P/E ratio and 24.94% ROE. Recent earnings showed mixed results with a Q1 2026 miss but strong beats in previous quarters. Analyst consensus remains positive with a $23.90 price target, while technical indicators show bearish momentum with key support at $16.
PBR presents a compelling value opportunity with deep discount valuation and robust cash flow generation supporting substantial dividends. However, recent earnings volatility and bearish technical signals suggest near-term pressure. The stock's 46% upside to consensus target offers significant potential, but investors should monitor execution on production growth targets and global oil price stability as key catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Petróleo Brasileiro SA
Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →
